These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10487527)

  • 1. Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands.
    Mukherjee A; Kirkovsky LI; Kimura Y; Marvel MM; Miller DD; Dalton JT
    Biochem Pharmacol; 1999 Oct; 58(8):1259-67. PubMed ID: 10487527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring.
    Kirkovsky L; Mukherjee A; Yin D; Dalton JT; Miller DD
    J Med Chem; 2000 Feb; 43(4):581-90. PubMed ID: 10691684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective binding of Casodex to the androgen receptor.
    Mukherjee A; Kirkovsky L; Yao XT; Yates RC; Miller DD; Dalton JT
    Xenobiotica; 1996 Feb; 26(2):117-22. PubMed ID: 8867996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.
    Yin D; He Y; Perera MA; Hong SS; Marhefka C; Stourman N; Kirkovsky L; Miller DD; Dalton JT
    Mol Pharmacol; 2003 Jan; 63(1):211-23. PubMed ID: 12488554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor.
    He Y; Yin D; Perera M; Kirkovsky L; Stourman N; Li W; Dalton JT; Miller DD
    Eur J Med Chem; 2002 Aug; 37(8):619-34. PubMed ID: 12161060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of nonsteroidal androgens.
    Dalton JT; Mukherjee A; Zhu Z; Kirkovsky L; Miller DD
    Biochem Biophys Res Commun; 1998 Mar; 244(1):1-4. PubMed ID: 9514878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
    Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
    J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
    Liu H; An X; Li S; Wang Y; Li J; Liu H
    Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
    de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
    ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
    Söderholm AA; Lehtovuori PT; Nyrönen TH
    J Med Chem; 2005 Feb; 48(4):917-25. PubMed ID: 15715462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
    Zhang Y; Wang XW; Jelovac D; Nakanishi T; Yu MH; Akinmade D; Goloubeva O; Ross DD; Brodie A; Hamburger AW
    Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9890-5. PubMed ID: 15994225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
    Krishnan AV; Zhao XY; Swami S; Brive L; Peehl DM; Ely KR; Feldman D
    Endocrinology; 2002 May; 143(5):1889-900. PubMed ID: 11956172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer.
    Yang J; Bohl CE; Nair VA; Mustafa SM; Hong SS; Miller DD; Dalton JT
    J Pharmacol Exp Ther; 2006 Apr; 317(1):402-8. PubMed ID: 16434567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.